Monte Rosa Therapeutics, Inc. GLUE
11.77
0.05
0.43%
as of 25 Sep
- Market cap
- $999.9M
- P/E
- 0.0×
Follow GLUE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (42.66%) | (32.62%) | (16.94%) | 9.28% |
+8 more TTM periods Free account |
|
| (30.67%) | (23.02%) | (8.71%) | 5.41% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(26.78%) | (20.48%) | (10.88%) | 5.69% | |
Average Days of Receivables |
62.51 | 39.17 | 34.24 | 9.98 | |
Free Cash Flow per Share |
(0.32) | (0.20) | (0.33) | 1.76 | |
Free Cash Flow |
(32.08) | (19.66) | (27.50) | 145.02 | |
Capital Expenditures |
(8.01) | (4.98) | (4.70) | (4.12) | |
Piotroski F-Score |
2.00 | 2.00 | 4.00 | 7.00 | |
| Other line items | |||||
Cash ROIC |
(2.17%) | (1.24%) | (3.74%) | 23.41% | |
Accounts Receivable Turnover |
7.88 | 14.28 | 21.01 | 65.30 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.02) | (0.01) | (0.03) | (0.05) | |
Research and Development Expense of Revenue |
594.18% | 357.09% | 114.42% | 76.23% | |
Selling, General and Administrative Expense of Revenue |
138.86% | 88.12% | 29.42% | 19.08% | |
Share Based Compensation of Revenue |
71.68% | 45.44% | 15.25% | 10.48% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.15 | 0.11 | 0.59 | 7.12 | |
Depreciation/Fixed assets |
0.27 | 0.29 | 0.32 | 0.30 | |
Capex/Depreciation |
(0.99) | (0.60) | (0.56) | (0.49) | |
Revenue per Share |
0.28 | 0.43 | 1.49 | 2.20 | |
Operating CF per Share |
(0.24) | (0.15) | (0.27) | 1.81 | |
Capex per Share |
(0.08) | (0.05) | (0.06) | (0.05) | |
Capex to Sales |
0.28 | 0.12 | 0.04 | 0.02 | |
Net Profit Margin |
(560.85%) | (302.69%) | (31.23%) | 11.54% |
Columns are period end dates